Linked Life Data

12564373

Source:http://linkedlifedata.com/resource/pubmed/id/12564373

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
21
pubmed:dateCreated
2003-2-4
pubmed:abstractText
Intermittent endocrine treatment or cyclic therapy of prostate cancer aims at prolonging survival by delaying progression to androgen independence and at improving quality of life by avoiding the side effects of continuous androgen ablation. Intermittent endocrine treatment is capable of inducing multiple apoptoic regressions and of improvement in quality of life including sexual functions. The recommended length of therapeutic period is 6-9 months. The mean off-therapy interval approaches 50% of the duration of the treatment cycle. The mean time to disease progression is 32 month. The definitive answer to the question of prolonged survival awaits the completion of ongoing randomized studies.
pubmed:language
cze
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0008-7335
pubmed:author
pubmed:issnType
Print
pubmed:day
25
pubmed:volume
141
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
669-72
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
[Intermittent androgen blockade in prostatic carcinoma].
pubmed:affiliation
Urologická klinika 1. LF UK a VFN, Praha. j.vit@email.cz
pubmed:publicationType
Journal Article, English Abstract